Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes;Traitement combiné par empaglifozine et linagliptine chez les patients atteints de diabète de type 2

Annales d'Endocrinologie

Volumn 77, Issue 5, 2016, Pages 557-562

  Tan, Xueying ^a   Hu, Jingbo ^b  

^a NINGBO UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Empagliflozin; Glyxambi ; Linagliptin; Type 2 diabetes

Indexed keywords

EMPAGLIFLOZIN; EMPAGLIFLOZIN PLUS LINAGLIPTIN; GLUCOSE; HEMOGLOBIN A1C; LINAGLIPTIN; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLUCOSIDE;

ANGIONEUROTIC EDEMA; ANTIDIABETIC ACTIVITY; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD PRESSURE; BODY WEIGHT; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; GASTROENTERITIS; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; KIDNEY MASS; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OSMOTIC DIURESIS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SIDE EFFECT; STEADY STATE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINARY EXCRETION; URINARY TRACT INFECTION; URTICARIA; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY;

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; LINAGLIPTIN;

EID: 84962497651     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2015.11.003     Document Type: Article

References (34)

1. [1] American Diabetes Association, Standards of medical care in diabetes–2012. Diabetes Care 35 (2012), S11–S63.
2. [2] Defronzo, R.A., Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58 (2009), 773–795.
3. 1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 55 (2012), 636–643.
4. [4] Scheen, A.J., Treatment of type 2 diabetes. Acta Clin Belg 58 (2003), 318–324.
5. [5] Rosenstock, J., Hansen, L., Zee, P., et al. Dual add-on therapy in poorly controlled type 2 diabetes on metformin: randomized, double-blind trial of saxagliptin + dapagliflozin vs saxagliptin and dapagliflozin alone. Diabetes Care 38 (2015), 376–383.
6. [6] Grempler, R., Thomas, L., Eckhardt, M., et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14 (2012), 83–90.
7. [7] Gallwitz, B., Linagliptin – a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy. Clin Med Insights Endocrinol Diabetes 5 (2012), 1–11.
8. [8] Mather, A., Pollock, C., Glucose handling by the kidney. Kidney Int Suppl 120 (2011), S1–S6.
9. [9] Scott, L.J., Empagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs 74 (2014), 1769–1784.
10. [10] Ferrannini, E., Seman, L., Seewaldt-Becker, E., et al. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 15 (2013), 721–728.
11. [11] Roden, M., Weng, J., Eilbracht, J., et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 1 (2013), 208–219.
12. [12] Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128 [Epub ahead of print].
13. [13] Forst, T., Pfützner, A., Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes. Expert Opin Pharmacother 13 (2012), 101–110.
14. [14] Taskinen, M.R., Rosenstock, J., Tamminen, I., et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 13 (2011), 65–74.
15. [15] Barnett, A.H., Patel, S., Harper, R., et al. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension. Diabetes Obes Metab 14 (2012), 1145–1154.
16. [16] Van Genugten, R.E., van Raalte, D.H., Diamant, M., Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. Diabetes Obes Metab 14 (2012), 101–111.
17. [17] Deacon, C.F., Holst, J.J., Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs 19 (2010), 133–140.
18. [18] Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., et al. Management of hyperglycaemia in type 2 diabetes (2015): a patient-centered approach. Update to a position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care 38 (2015), 140–149.
19. [19] Garber, A.J., Abrahamson, M.J., Barzilay, J.I., et al. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement–executive summary. Endocr Pract 19 (2013), 536–557.
20. [20] Merovci, A., Solis-Herrera, C., Daniele, G., et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Investig 124 (2014), 509–514.
21. [21] Ferrannini, E., Muscelli, E., Frascerra, S., et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Investig 124 (2014), 499–508.
22. [22] Nathan, D.M., Buse, J.B., Davidson, M.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32 (2009), 193–203.
23. [23] Lewin, A., DeFronzo, R.A., Patel, S., Liu, D., et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care 38 (2015), 394–402.
24. [24] Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 (2013), 587–597.
25. [25] DeFronzo, R.A., Lewin, A., Patel, S., et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 38 (2015), 384–393.
26. [26] Friedrich, C., Metzmann, K., Rose, P., et al. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther 35 (2013), A33–A42.
27. [27] GlaxoSmithKline, Empagliflozin and linagliptin (GLYXAMBI): US prescribing information. 2015 [Accessed 2 Feb 2015] http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206073s000lbl.pdf.
28. [28] Brand, T., Macha, S., Mattheus, M., et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Adv Ther 29 (2012), 889–899.
29. [29] Macha, S., Mattheus, M., Pinnetti, S., et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and glimepiride following co-administration in healthy volunteers: a randomised, open-label, crossover study. Diabetes Res Clin Metab, 1, 2012, 14.
30. [30] Barnett, A.H., Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus. Postgrad Med 125 (2013), 92–100.
31. [31] Chen, G., McAlister, F.A., Walker, R.L., et al. Cardiovascular outcomes in Framingham participants with diabetes: the importance of blood pressure. Hypertension 57 (2011), 891–897.
32. [32] Schrier, R.W., Estacio, R.O., Esler, A., et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61 (2002), 1086–1097.
33. [33] Weber, M.A., Schiffrin, E.L., White, W.B., Mann, S., Lindholm, L.H., Kenerson, J.G., et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens 16 (2014), 14–26.
34. [34] James, P.A., Oparil, S., Carter, B.L., Cushman, W.C., Dennison Himmelfarb, C., Handler, J., et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311 (2014), 507–520.